deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04270175

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Sponsor: Janssen Scientific Affairs, LLC

Conditions AL Amyloidosis Amyloid Refractory AL Amyloidosis
Interventions Daratumumab SC Dexamethasone Pomalidomide
Updated 16 times since 2020 Last updated: Feb 25, 2026 Started: Apr 14, 2021 Primary completion: Jan 31, 2027 Completion: Jan 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04270175, this PHASE2 trial focuses on AL Amyloidosis and Amyloid and remains ongoing. Sponsored by Janssen Scientific Affairs, LLC, it has been updated 16 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Aug 2023 · 13 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Nov 2025 · 5 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

16 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 11 earlier versions

  1. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Jul 2022 — Aug 2023 [monthly]

    Recruiting PHASE2

  3. Sep 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  4. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Feb 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2

  7. Sep 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  8. Aug 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

  9. May 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

  10. Apr 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE2

  11. Mar 2020 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Scientific Affairs, LLC
  • Weill Medical College of Cornell University
Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations